This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
CAPItello-281 Trial
PSMAddition Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Biochemical Recurrence in Prostate Cancer
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Science in GU Oncology
Bishoy M. Faltas, MD
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Newsletter Archive
GU Onc Weekly
Go
Reset
Send Date
Subject
Created Date
ID
Asc
Desc
Advancing Treatment Through New Targets and Modalities in Prostate Cancer
Sent on 22 July 2026
Emerging Multimodal Strategies in Localized Prostate Cancer
Sent on 21 July 2026
When Should Genomic Risk Prompt Treatment Intensification?
Sent on 18 July 2026
UroAlert - GU Oncology Weekly
Sent on 16 July 2026
The Next Generation of Targeted Therapies in Prostate Cancer
Sent on 16 July 2026
Advancing Prostate Radiotherapy Through Training and Innovation
Sent on 14 July 2026
Optimizing Management of Low-Grade Intermediate-Risk NMIBC
Sent on 12 July 2026
Integrating Biomarkers Into Treatment Decisions in mCRPC
Sent on 11 July 2026
Advances in Bladder Preservation for High-Risk BCG-Unresponsive NMIBC
Sent on 10 July 2026
UroAlert - GU Oncology Weekly
Sent on 09 July 2026
Managing Recurrence Burden After BCG in High-Risk NMIBC
Sent on 08 July 2026
Comorbidities and CV Risk in ARPI Selection for mHSPC
Sent on 07 July 2026
Assessing Response to PSMA-Targeted Radioligand Therapy
Sent on 06 July 2026
Optimizing TURBT Quality and Recurrence Prevention in NMIBC
Sent on 03 July 2026
UroAlert - GU Oncology Weekly
Sent on 02 July 2026
Genomic Risk Across the Prostate Cancer Continuum
Sent on 02 July 2026
Biomarker-Driven Treatment in mHSPC: PTEN Loss, Testing, and Treatment Selection
Sent on 01 July 2026
Introducing Science in GU Oncology, A Monthly Newsletter from Bishoy M. Faltas, MD
Sent on 30 June 2026
Evolving First-Line Strategies in mHSPC: Intensification, Tumor Biology, and Molecular Testing
Sent on 29 June 2026
Using Genomic Classifiers to Guide Prostate Cancer Treatment Decisions
Sent on 27 June 2026
UroAlert - GU Oncology Weekly
Sent on 25 June 2026
LEGION-100 Trial-in-Progress Portal Now Available on UroToday
Sent on 25 June 2026
Detection, Surveillance, and Risk-Adapted Management in NMIBC
Sent on 24 June 2026
Individualizing Systemic Therapy Strategies in Prostate Cancer
Sent on 23 June 2026
Optimizing PSMA Radioligand Therapy in Advanced Prostate Cancer
Sent on 22 June 2026
Individualizing Treatment Intensification in mHSPC
Sent on 21 June 2026
Evolving Strategies in Localized Prostate Cancer: Treatment Intensification, Imaging, and Risk Stratification
Sent on 19 June 2026
UroAlert - GU Oncology Weekly
Sent on 18 June 2026
Bladder-Sparing Treatment Decisions in BCG-Unresponsive NMIBC
Sent on 18 June 2026
Biomarkers, EZH2 Targeting, and Treatment Selection in Advanced Prostate Cancer
Sent on 17 June 2026
From Mechanism to Practice: Radiopharmaceutical Therapy in Prostate Cancer
Sent on 16 June 2026
High-Risk NMIBC: Bladder Preservation, BCG Challenges, and Evolving Treatment Pathways
Sent on 13 June 2026
FDA Approval in PTEN-Deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer
Sent on 12 June 2026
Experts Discuss Bladder Cancer Controversies: Rapid-Fire Debates
Sent on 12 June 2026
UroAlert - GU Oncology Weekly
Sent on 11 June 2026
Patient Selection, Imaging, and Sequencing in PSMA-Targeted Prostate Cancer Care
Sent on 11 June 2026
Investigational Approaches in Advanced Prostate Cancer
Sent on 10 June 2026
Improving Bladder-Sparing Decisions in NMIBC
Sent on 09 June 2026
UroAlert - GU Oncology Weekly
Sent on 04 June 2026
Rethinking Treatment Pathways in Recurrent Low-Grade NMIBC
Sent on 04 June 2026
ASCO 2026 Radioligand Therapy Advances Across Prostate Cancer
Sent on 02 June 2026
ASCO 2026 Prostate Cancer Advances Across the Disease Continuum
Sent on 01 June 2026
ASCO 2026 Advancing Curative Strategies in Bladder and Kidney Cancer
Sent on 01 June 2026
Key Prostate Cancer Insights From Day 3 at ASCO
Sent on 31 May 2026
ASCO 2026 Matching Prostate Cancer Treatment to Risk, Response, and Patient Benefit
Sent on 31 May 2026
Novel Approaches to Curing Bladder and Kidney Cancer at ASCO 2026
Sent on 30 May 2026
Emerging RCC and Bladder Cancer Data From ASCO Day 1
Sent on 30 May 2026
UroAlert - GU Oncology Weekly
Sent on 28 May 2026
Navigating Treatment Decisions as Prostate Cancer Progresses
Sent on 28 May 2026
Emerging Strategies Shaping PSMA-Directed Prostate Cancer Care
Sent on 27 May 2026
Page
of 59
Display #
5
10
15
20
25
30
50
100
Results 1 - 50 out of 2937
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
